We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cell Lines Available for Research

By Biotechdaily staff writers
Posted on 23 Oct 2005
Nine cell lines are available to commercial and academic researchers worldwide who are seeking a cure for lymphoma, leukemia, pancreatic cancer, or macroglobulinema.

The cell lines were developed by researchers at the Barbara Ann Karmanos Cancer Institute of Wayne State University (Detroit, MI, USA) and are being distributed by Asterand, Inc. (Detroit, MI, USA; www.asterand.com). Asterand also markets breast cancer cell lines under license from the University of Michigan (Ann Arbor, USA) and prostate cancer lines from Onyvax (London, UK). The company acquires donated samples from a world-wide network of collaborating hospitals and clinics.

Following are the cell lines available: Waldenstrom's macroglobulinema, follicular small cleaved cell lymphoma, diffuse large cell lymphoma (chemo-resistant), acute lymphoblastic leukemia (early stage), acute myeloid leukemia, pancreatic cancer, diffuse large cell lymphoma, Burkitt's lymphoma, and nodal histiocytic lymphoma (intermediate grade).

"These cell lines are very good model systems for diseases they are derived from,” said Dr. James Eliason, chief scientific officer of Asterand. "They have been studied extensively by researchers at Wayne State University and elsewhere, which is evident by the fact that there are over 50 publications related to them. In addition to common cancers, these cell lines are great resources for studying rare cancers such as Burkitt's lymphoma, which affects children and young people, aged 12-30, or pancreatic cancer, which is probably one of the most difficult cancers to detect.”




Related Links:
Asterand

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Hemodynamic System Monitor
OptoMonitor

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
23 Oct 2005  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
23 Oct 2005  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
23 Oct 2005  |   BioResearch